Your browser doesn't support javascript.
loading
Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial.
Davids, Matthew S; Brander, Danielle M; Kim, Haesook T; Tyekucheva, Svitlana; Bsat, Jad; Savell, Alexandra; Hellman, Jeffrey M; Bazemore, Josie; Francoeur, Karen; Alencar, Alvaro; Shune, Leyla; Omaira, Mohammad; Jacobson, Caron A; Armand, Philippe; Ng, Samuel; Crombie, Jennifer; LaCasce, Ann S; Arnason, Jon; Hochberg, Ephraim P; Takvorian, Ronald W; Abramson, Jeremy S; Fisher, David C; Brown, Jennifer R.
Afiliación
  • Davids MS; Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, MA, USA. Electronic address: matthew_davids@dfci.harvard.edu.
  • Brander DM; Duke University Medical Center, Department of Medicine, Durham, NC, USA.
  • Kim HT; Dana-Farber Cancer Institute, Department of Data Sciences, Harvard T H Chan School of Public Health, Department of Biostatistics, Boston, MA, USA.
  • Tyekucheva S; Dana-Farber Cancer Institute, Department of Data Sciences, Harvard T H Chan School of Public Health, Department of Biostatistics, Boston, MA, USA.
  • Bsat J; Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, MA, USA.
  • Savell A; Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, MA, USA.
  • Hellman JM; Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, MA, USA.
  • Bazemore J; Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, MA, USA.
  • Francoeur K; Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, MA, USA.
  • Alencar A; University of Miami Sylvester Comprehensive Cancer Center, Department of Hematology and Oncology, Miami, FL, USA.
  • Shune L; University of Kansas Cancer Center, Department of Hematologic Malignancies, Westwood, KS, USA.
  • Omaira M; West Michigan Cancer Center, Department of Medical Oncology, Kalamazoo, MI, USA.
  • Jacobson CA; Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, MA, USA.
  • Armand P; Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, MA, USA.
  • Ng S; Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, MA, USA.
  • Crombie J; Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, MA, USA.
  • LaCasce AS; Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, MA, USA.
  • Arnason J; Beth Israel Deaconess Medical Center, Department of Medical Oncology, Boston, MA, USA.
  • Hochberg EP; Massachusetts General Hospital, Department of Medical Oncology, Boston, MA, USA.
  • Takvorian RW; Massachusetts General Hospital, Department of Medical Oncology, Boston, MA, USA.
  • Abramson JS; Massachusetts General Hospital, Department of Medical Oncology, Boston, MA, USA.
  • Fisher DC; Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, MA, USA.
  • Brown JR; Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, MA, USA.
Lancet Haematol ; 6(8): e419-e428, 2019 Aug.
Article en En | MEDLINE | ID: mdl-31208944
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Pirazoles / Pirimidinas / Vidarabina / Leucemia Linfocítica Crónica de Células B / Protocolos de Quimioterapia Combinada Antineoplásica / Ciclofosfamida / Inhibidores de Proteínas Quinasas / Rituximab Tipo de estudio: Clinical_trials / Etiology_studies / Guideline / Prognostic_studies Límite: Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Haematol Año: 2019 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Pirazoles / Pirimidinas / Vidarabina / Leucemia Linfocítica Crónica de Células B / Protocolos de Quimioterapia Combinada Antineoplásica / Ciclofosfamida / Inhibidores de Proteínas Quinasas / Rituximab Tipo de estudio: Clinical_trials / Etiology_studies / Guideline / Prognostic_studies Límite: Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Haematol Año: 2019 Tipo del documento: Article